Hudson Bay Capital Management LP Has Lifted Biomarin Pharmaceutical (BMRN) Holding By $8.32 Million; Torchmark (TMK) Sentiment Is 0.82

February 18, 2018 - By Maria Brooks

Hudson Bay Capital Management Lp increased Biomarin Pharmaceutical Inc (BMRN) stake by 93.23% reported in 2017Q3 SEC filing. Hudson Bay Capital Management Lp acquired 89,500 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 0.71%. The Hudson Bay Capital Management Lp holds 185,500 shares with $17.26M value, up from 96,000 last quarter. Biomarin Pharmaceutical Inc now has $14.92 billion valuation. The stock decreased 0.16% or $0.14 during the last trading session, reaching $84.98. About 779,400 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since February 18, 2017 and is uptrending. It has underperformed by 11.41% the S&P500.

Torchmark Corporation, through its subsidiaries, provides various life and health insurance products, and annuities in the United States, Canada, and New Zealand. The company has market cap of $10.00 billion. It operates through Life Insurance, Health Insurance, and Annuities divisions. It has a 7.09 P/E ratio. The Life Insurance segment offers life insurance products, including traditional and interest-sensitive whole life and term life insurance, and other life insurance.

Barbara Oil Co. holds 3.73% of its portfolio in Torchmark Corporation for 67,500 shares. Spf Beheer Bv owns 906,971 shares or 3.06% of their US portfolio. Moreover, Prospector Partners Llc has 1.82% invested in the company for 149,700 shares. The Alabama-based Regions Financial Corp has invested 1.73% in the stock. Leavell Investment Management Inc., a Alabama-based fund reported 132,962 shares.

Ratings analysis reveals 0 of Torchmark’s analysts are positive. Out of 2 Wall Street analysts rating Torchmark, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. TMK was included in 2 notes of analysts from October 7, 2016. Bank of America downgraded the stock to “Underperform” rating in Friday, November 18 report. Credit Suisse initiated the stock with “Neutral” rating in Friday, October 7 report.

The stock increased 0.62% or $0.53 during the last trading session, reaching $86.65. About 698,247 shares traded or 13.65% up from the average. Torchmark Corporation (TMK) has risen 25.88% since February 18, 2017 and is uptrending. It has outperformed by 9.18% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 13 sales for $26.30 million activity.

Since September 15, 2017, it had 0 insider buys, and 9 insider sales for $9.10 million activity. Shares for $1.34 million were sold by FUCHS HENRY J on Tuesday, January 2. The insider LAWLIS V BRYAN sold $333,150. 10,000 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares with value of $903,203 were sold by BIENAIME JEAN JACQUES. On Thursday, December 14 HERON ELAINE J sold $71,116 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 800 shares. 30,000 shares valued at $2.72 million were sold by Davis George Eric on Thursday, February 1. Another trade for 18,415 shares valued at $1.70M was made by BAFFI ROBERT on Thursday, September 28. $334,495 worth of stock was sold by Ajer Jeffrey Robert on Friday, September 22.

Hudson Bay Capital Management Lp decreased Callaway Golf Co (NYSE:ELY) stake by 530,398 shares to 200,173 valued at $2.89M in 2017Q3. It also reduced Sabra Health Care Reit Inc (NASDAQ:SBRA) stake by 235,642 shares and now owns 854,358 shares. Arbutus Biopharma Corp was reduced too.

Investors sentiment decreased to 1.13 in Q3 2017. Its down 0.13, from 1.26 in 2017Q2. It turned negative, as 40 investors sold BMRN shares while 116 reduced holdings. 45 funds opened positions while 132 raised stakes. 171.51 million shares or 2.04% more from 168.09 million shares in 2017Q2 were reported. Massachusetts Fincl Services Ma holds 0.04% or 916,325 shares. Tarbox Family Office, a California-based fund reported 1,020 shares. Clearbridge Limited has 790 shares for 0% of their portfolio. Moreover, Fort Washington Inv Advsr Oh has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Hudson Bay Management LP has invested 0.43% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Axa reported 384,866 shares. Moreover, Invesco has 0.15% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 4.49 million shares. First Personal Services invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The Maryland-based Price T Rowe Assocs Md has invested 0.03% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Next Finance Gru owns 1,740 shares or 0.05% of their US portfolio. Gotham Asset Mngmt Ltd Llc holds 0% or 3,590 shares. Paloma Prtn Mngmt stated it has 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Grandfield And Dodd Limited Com invested in 0.07% or 6,497 shares. Macquarie Limited reported 40,713 shares. Eagle Asset holds 0.17% or 320,064 shares.

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical had 78 analyst reports since August 5, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Buy” rating and $11100 target in Thursday, July 6 report. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Thursday, October 19 by SunTrust. The rating was initiated by Citigroup on Wednesday, August 30 with “Buy”. The company was maintained on Monday, October 5 by Wedbush. The rating was maintained by Stifel Nicolaus on Wednesday, October 18 with “Buy”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Leerink Swann on Tuesday, July 18. The stock has “Perform” rating by Oppenheimer on Wednesday, November 25. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Neutral” rating given on Tuesday, August 25 by Wedbush. As per Thursday, September 14, the company rating was reinitiated by PiperJaffray. As per Thursday, October 19, the company rating was maintained by Leerink Swann.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: